TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01607879
Drug: Standard of care ADT + (HMB + arginine + glutamine)
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months
Study: NCT00474721
Drug: acetaminophen with codeine
Normalized name: acetaminophen with codeine ORAL ELIXIR
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01778062
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150µg once daily oral inhalation
Study: NCT01778062
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo once daily oral inhalation
Study: NCT02088957
Drug: Brivaracetam intravenous solution
Normalized name: brivaracetam Oral Solution
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Solution for infusion~* Concentration: 10 mg/mL~* Route of Administration: Intravenous bolus use
Study: NCT02088957
Drug: Brivaracetam oral tablets
Normalized name: brivaracetam Oral Tablet
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~* Route of Administration: Oral use
Study: NCT00702962
Drug: Vorinostat, Carboplatin, Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total.
Study: NCT03031496
Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side.
Study: NCT03031496
Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)
Normalized name: amiloride hydrochloride / hydrochlorothiazide Oral Tablet [Moduretic]
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917.
Study: NCT00895557
Drug: chantix
Normalized name: Chantix
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
Study: NCT01941004
Drug: fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Study: NCT01941004
Drug: Placebo (6mos) + open label fingolimod (6 mos)
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Study: NCT01054196
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: daily dose dependent on dose-escalation schedule
Study: NCT01054196
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 given Days -2 and -1
Study: NCT03796013
Drug: Entrectinib Form A
Normalized name: entrectinib
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single oral dose of entrectinib form A under fasted conditions.
Study: NCT03796013
Drug: Entrectinib Form C
Normalized name: entrectinib
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single oral dose of entrectinib form C under fasted conditions.
Study: NCT00655330
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (160mg/day)
Study: NCT00655330
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol (750mg/day)
Study: NCT02133924
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab 300mg on days 0 and 14.
Study: NCT01728805
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00322075
Drug: insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00241046
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01533818
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)\* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0
Study: NCT01533818
Drug: Sugar Syrup
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It will be given 2 times/day for 7 days
Study: NCT02574845
Drug: Metformin HCl
Normalized name: metformin HCl
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02574845
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02277184
Drug: Ficlatuzumab
Normalized name: Ficlatuzumab
DrugBank: Ficlatuzumab (DB11680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)
Study: NCT02277184
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes.
Study: NCT01956604
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00350038
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00350038
Drug: Ciprofibrate
Normalized name: ciprofibrate
DrugBank: Ciprofibrate (DB09064)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05431218
Drug: Cholecalciferol Liquid
Normalized name: cholecalciferol Oral Liquid Product
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily single dose of the drug in the first half of the day in an individually selected dose for 3 months
Study: NCT02812940
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GvHD prophylaxis
Study: NCT01853475
Drug: PQP tablets 960mg
Normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Piperaquine phosphate tablets 960mg
Study: NCT01853475
Drug: PQP tablets 1440mg
Normalized name: pegvaliase-pqpz
DrugBank: Pegvaliase (DB12839)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Piperaquine phosphate tablets 1440mg
Study: NCT01853475
Drug: OZ439+TPGS 800mg
Normalized name: TPGS
DrugBank: Tocofersolan (DB11635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OZ439+TPGS prototype formulation 800mg
Study: NCT01853475
Drug: OZ439 PIB 800mg
Normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 Powder in Bottle Aqueous Solution 800mg
Study: NCT01093677
Drug: LIM-0705
Normalized name: Landiololumhttps://lims.drugbank.com/drugs/DB12212/edit#
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Oral solution 750 mg LIM 0705 BID for 14 days.
Study: NCT01695122
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01630343
Drug: Paracetamol tablet and Tramadol capsule
Normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
Study: NCT01630343
Drug: Panadol 500mg tablet, tramadol 50mg capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
Study: NCT04039503
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC as add-on to the pre-trial background medication.
Study: NCT01097460
Drug: MM-111 + Herceptin
Normalized name: Herceptin
DrugBank: MM-111 (DB17983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
Study: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00013%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
Study: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00033%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
Study: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.001%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Study: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.00267%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
Study: NCT01298687
Drug: Travoprost Ophthalmic Solution, 0.004%
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01298687
Drug: Travoprost Vehicle
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inactive ingredients used as an active comparator
Study: NCT00310557
Drug: Gadopentetate dimeglumine (Magnevist)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study: NCT03596762
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY3427080 capsules
Study: NCT01213173
Drug: Succinate Metoprolol (Betaloc ZOK®)
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
Study: NCT01213173
Drug: Succinate Metoprolol (Betaloc ZOK®)
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
Study: NCT00643292
Drug: amoxicillin/clavulanate postassium (Augmentin ES-600)
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
Study: NCT00227942
Drug: Estrogen Replacement Therapy
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17-b-Estradiol Patch, .05 mg/day; applied for 7 days
Study: NCT00227942
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day, po qhs
Study: NCT00214019
Drug: salmeterol
Normalized name: Salmeterol
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: salmeterol diskus 50 mcg twice per day
Study: NCT00214019
Drug: Fluticasone
Normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo diskus, fluticasone MDI 88 mcg twice per day
Study: NCT01179152
Drug: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
Study: NCT01346072
Drug: tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral, 30 mg, single dose, one time administration
Study: NCT00669877
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
Study: NCT00669877
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
Study: NCT00669877
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
Study: NCT00669877
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mcg/kg
Study: NCT00669877
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
Study: NCT01492153
Drug: biphasic human insulin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Study: NCT00286806
Drug: AT-101
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03017235
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Study: NCT02043730
Drug: Nab-paclitaxel and Gemcitabine
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
Study: NCT02043730
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
Study: NCT01646177
Drug: 50 mg etanercept
Normalized name: etanercept 50 MG/ML
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT01646177
Drug: 80 mg ixekizumab
Normalized name: ixekizumab 80 MG/ML
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT03536507
Drug: ACETAZOLAMIDE oral capsule
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Study: NCT03990077
Drug: HL-085
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HL-085 ( Capsule) is one MEK inhibitor.
Study: NCT03990077
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
Study: NCT03432442
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin once every 24 hours for three administrations
Study: NCT00668265
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage is 50 - 300 mg, once daily, at bedtime.
Study: NCT01613482
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly, 2mg/kg of corporal weight
Study: NCT01613482
Drug: Other chemotherapy in association with Trastuzumab
Normalized name: antibiotics in combination with other drugs
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
Study: NCT04596839
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir INN 100 mg lyophilized powder for infusion
Study: NCT00519246
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline 5 ml administrated intravenously
Study: NCT01699113
Drug: YF476
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg.
Study: NCT01699113
Drug: Rabeprazole
Normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~* YF476 100 mg; or~* rabeprazole 20 mg; or~* a combination of YF476 100 mg and rabeprazole 20 mg.
Study: NCT00056277
Drug: lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05538026
Drug: Mesalazine
Normalized name: mesalazine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily dose of 3 g (2 g orally + 1 g rectally)
Study: NCT00519246
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen Axetil 50 mg i.v.
Study: NCT00519246
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen Axetil 100 mg i.v.
Study: NCT00476164
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 doses of 1g 14 days apart
Study: NCT02351440
Drug: duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be randomized to receive either duloxetine or placebo
Study: NCT00440180
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg qd for 4 months
Study: NCT00030433
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00030433
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01985425
Drug: Colchicine 0.6 mg
Normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985425
Drug: Placebo Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01562847
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with 800 mg nilotinib daily.
Study: NCT01274325
Drug: Seretide
Normalized name: seractide
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
Study: NCT03069820
Drug: docetaxel and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive TP (docetaxel and cisplatin) chemotherapy
Study: NCT00968071
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m\^2 IV over an hour and half daily for 5 days.
Study: NCT00968071
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 mg/m\^2 IV on day 5.